Sudeep Pharma Board Approves Q1 FY27 Unaudited Financial Results
Sudeep Pharma Limited announced that its Board of Directors, in a meeting held on August 4, 2026, has approved the Unaudited Standalone & Consolidated Financial Results for the first quarter ended June 30, 2026. The board meeting commenced at 3:40 p.m. and concluded at 5:50 p.m. The company's compliance officer, Dimple Mehta, submitted the financials. The review report from SR and Co. Chartered Accountants indicates that based on their review, nothing has come to their attention that causes them to believe the financial statements contain material misstatements, though two subsidiaries' results, amounting to ₹1,139.55 lakhs in revenue and ₹49.12 lakhs in net loss, were not reviewed and were deemed immaterial by management.
Key Highlights
- Board approved Q1 FY27 unaudited standalone and consolidated results.
- Financial results for the quarter ended June 30, 2026, were considered.
- Auditors provided a limited review report on the consolidated results.
- Two subsidiaries' results were not reviewed but deemed immaterial.
- The filing complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Price Impact
More from SUDEEPPHRM